Document Type

Article

Publication Date

12-21-2013

Publication Title

BioMed Central Cancer

Abstract

Chk1 inhibitors have emerged as promising anticancer therapeutic agents particularly when combined with antimetabolites such as gemcitabine, cytarabine or hydroxyurea. Here, we address the importance of appropriate drug scheduling when gemcitabine is combined with the Chk1 inhibitor MK-8776, and the mechanisms involved in the schedule dependence.

DOI

10.1186/1471-2407-13-604

Share

COinS